跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
A-008
首页
药物
A-008
A-008
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9
申请人: CIVI BIOPHARMA INC
优先权: 2020
EP
US
WO
6 件公开
AXMI-008, a delta-endotoxin gene and methods for its use
申请人: ATHENIX CORP
优先权: 2004
US
6 件公开
ANTI-TUMOR AGENT OTX-008 TARGETS HUMAN GALECTIN-1
申请人: UNIV MINNESOTA
优先权: 2012
US
WO
2 件公开
Macrolides with antitumor activity
申请人: INST BIOMAR SA
优先权: 1997
US
Desugar and deaminosugar FR-008 derived polyketone antibiotics
申请人: UNIV SHANGHAI JIAOTONG
优先权: 2003
CN
Heptaene macrolide polyketone antibiotic FR-008 compound
申请人: UNIV SHANGHAI JIAOTONG
优先权: 2003
CN
COMPOUNDS INHIBITING GALECTIN-1 EXPRESSION, CANCER CELL PROLIFERATION, INVASION, AND TUMORIGENESIS
申请人: RAYMOND ERIC
优先权: 2012
US
Research on antitumor mechanism of Combretastatin A-4 derivative
申请人: UNIV CHINA PHARMA
优先权: 2016
CN
Method for preparing anhydride from trimellitic acid
申请人: CHINESE PETROCHEMICAL YANGTZE PETROCHEMICAL CO LTD
优先权: 2020
CN
Application of flavonoid derivative CPU-008 in preparation of anti-lymphoma medicine
申请人: UNIV CHINA PHARMA
优先权: 2021
CN
第 1 / 3 页
上一页
下一页
药物
反馈